Elanco Files Routine 8-K; Confirms Non-Emerging Growth Status
Ticker: ELAN · Form: 8-K · Filed: Jan 2, 2024 · CIK: 1739104
| Field | Detail |
|---|---|
| Company | Elanco Animal Health Inc (ELAN) |
| Form Type | 8-K |
| Filed Date | Jan 2, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, administrative, 8-K
TL;DR
**Elanco's 8-K is a standard administrative filing with no new material news.**
AI Summary
Elanco Animal Health Incorporated filed an 8-K on January 2, 2024, primarily to disclose general corporate information and confirm its status as a non-emerging growth company. This filing, under SEC File Number 001-38661, indicates standard compliance and does not reveal new financial or operational events. For investors, this means there are no immediate new developments, positive or negative, that would significantly impact their investment decision based solely on this filing.
Why It Matters
This filing is largely administrative, confirming Elanco's status and providing contact information, which means no new material information affecting the stock price is disclosed.
Risk Assessment
Risk Level: low — This 8-K is a routine administrative filing and does not introduce any new financial or operational risks.
Analyst Insight
Investors should note this is a standard administrative filing and does not contain new material information that would warrant immediate action. Continue to monitor for future filings that may contain financial results or strategic announcements.
Key Players & Entities
- Elanco Animal Health Incorporated (company) — the registrant filing the 8-K
- January 2, 2024 (date) — date of earliest event reported and filing date
- 001-38661 (dollar_amount) — Commission File Number for Elanco
- ELAN (company) — trading symbol for Elanco's common stock
- New York Stock Exchange (company) — exchange where Elanco's common stock is registered
FAQ
What is the purpose of Elanco Animal Health Incorporated's 8-K filing dated January 2, 2024?
The 8-K filing by Elanco Animal Health Incorporated on January 2, 2024, is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, primarily disclosing general corporate information under 'Regulation FD Disclosure' and 'Financial Statements and Exhibits' items. It also confirms the company's status regarding 'emerging growth company' definition.
What is Elanco Animal Health Incorporated's trading symbol and on which exchange is it registered?
Elanco Animal Health Incorporated's common stock, with no par value, trades under the symbol 'ELAN' and is registered on the New York Stock Exchange.
What is the address and telephone number of Elanco Animal Health Incorporated's principal executive offices?
The principal executive offices of Elanco Animal Health Incorporated are located at 2500 Innovation Way, Greenfield, Indiana 46140. The registrant's telephone number is (877) 352-6261.
Is Elanco Animal Health Incorporated considered an 'emerging growth company' according to this filing?
No, the filing indicates with an unchecked box that Elanco Animal Health Incorporated is not an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
What is the Central Index Key (CIK) for Elanco Animal Health Incorporated?
The Central Index Key (CIK) for Elanco Animal Health Incorporated is 0001739104.
Filing Stats: 523 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2024-01-02 09:07:42
Filing Documents
- tm2334009d1_8k.htm (8-K) — 26KB
- tm2334009d1_ex99-1.htm (EX-99.1) — 11KB
- tm2334009d1_ex99-1img001.jpg (GRAPHIC) — 4KB
- 0001104659-24-000140.txt ( ) — 217KB
- elan-20240102.xsd (EX-101.SCH) — 3KB
- elan-20240102_lab.xml (EX-101.LAB) — 35KB
- elan-20240102_pre.xml (EX-101.PRE) — 22KB
- tm2334009d1_8k_htm.xml (XML) — 3KB
01
Item 7.01 Regulation FD Disclosure. A copy of the press release issued by Elanco Animal Health Incorporated (the "Company") announcing certain planned Board of Director and Committee leadership changes and proposed voting standard change is attached to this Current Report on Form 8-K as Exhibit 99.1. The information in this Item 7.01, including the information contained in the accompanying Exhibit 99.1, is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, and shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as otherwise expressly stated in such filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by Elanco Animal Health Incorporated dated January 2, 2024 104.1 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ELANCO ANIMAL HEALTH INCORPORATED Date: January 2, 2024 By: /s/ Todd Young Name: Todd Young Title: Executive Vice President and Chief Financial Officer